New hope for lung cancer patients when First-Line drug fails
NCT ID NCT07199010
Summary
This study aims to gather real-world information on how well the drug taletrectinib works and how safe it is for people with advanced ROS1-positive non-small cell lung cancer. It focuses on patients whose cancer has continued to grow despite treatment with another targeted drug called entrectinib. Doctors will observe and collect data from about 50 patients who are already receiving taletrectinib as part of their standard care.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai East Hospital (The East Hospital Affiliated to Tongji University)
Shanghai, Shanghai Municipality, 200120, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.